{"name":"Reata, a wholly owned subsidiary of Biogen","slug":"reata-a-wholly-owned-subsidiary-of-biogen","ticker":"","exchange":"","domain":"","description":"Reata, a subsidiary of Biogen, focuses on the development of innovative therapies for patients with serious diseases. Despite having two discontinued drug candidates, the company continues to explore new opportunities in its therapeutic areas.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQVXZFWHlaaFg0dGlFLWV1VVlPZVpVTGxlUnRKeE8wUXlEN0g2aGk1cTRjUnBXRkhNOFN2U0lSN2pWUUs5bHRPMzVnRXhSaTV0QlcwMVduT3BBb21LZWtYaDJvbk1VcUptdW0tZDkydGtvcER1bnhDcGdFRXY4UmNJV0I3UVRBTDBhTlBfMjBTdTVTZl8wcHZTUVpfWFR1VFRkclZocVQ2bGRDVUg0U1hhbUxnazVQUDZsOC1YTXN6YUdaZDRKNUJqdXI1cW4tUUpPN0RqdDc2ZXNqbG8?oc=5","date":"2024-09-12","type":"pipeline","source":"European Medical Journal","summary":"The Importance of Early Recognition, Diagnosis, and Treatment of Friedreich Ataxia - European Medical Journal","headline":"The Importance of Early Recognition, Diagnosis, and Treatment of Friedreich Ataxia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPS0FGSE9VVlItdGZlbk05d2JOaHpQY1BKdHRpSjBwaDY4UmxzRkdXOG9vb0MyM1dYdFhfMVl2UHczNk5pNGZ5Z0xBaUVsaVZZZUljOFh4aXdzVUdPa25TOWh2amtFYU5lRWhZWUxVTUlUQzJ4eERIdE9YamJsNVI1SkJwbkVCNFNUNUJZd1V2Z0ZWV2hqdlg2ZHV3?oc=5","date":"2024-06-26","type":"deal","source":"Pharmaceutical Technology","summary":"Pharma M&A: The top high value deals in 2023 - Pharmaceutical Technology","headline":"Pharma M&A: The top high value deals in 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPNVNGWHRnUFRYeUlCUm1xM1k1R3UtOHhDYXE4MUlacHRvVjQ5anJSbGxudEhkbVYzRloyaWhPVzh1WUljWm1KSnIzVlpsaXRTS3VIdC1SaXhwQTJhYjFRR2NFSDhFTXIxNDV5OGNuOWpfSGRaZ3BjWnBLLTFtaC1Zeg?oc=5","date":"2024-02-05","type":"deal","source":"Fierce Pharma","summary":"The top 10 biopharma M&A deals of 2023 - Fierce Pharma","headline":"The top 10 biopharma M&A deals of 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOaTk5c0Z6RHp6R1FaMlJTQnBWcUd0TjJVaG9CakYtWmp5M0FSQVN0a1RRRHp3Z0diNnBIZThPRnNia0pmTGVLYi0zXzhOdnIzZ3FKUWh4YTRwR3cxSjBxR0RqSHpsVEVUMkZKTXhPX0M1cFBzMzljVGt5bXlYNnBoSk00enV5ckdXVFl4V2hOUHZzdw?oc=5","date":"2023-10-12","type":"pipeline","source":"BioSpace","summary":"Biogen Lays Off 113 Reata Employees Weeks After Completing $7B Acquisition - BioSpace","headline":"Biogen Lays Off 113 Reata Employees Weeks After Completing $7B Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQNWowNUVSWldvektzbFAxbGtoUDE2STNzMFFvWENIbzV6eGZQSmw1cnJLYmhfX2ZVak1DeEJhZUE0Mi1RbjlLRWlHTHd5V2VYWEg1ODg2U0N5V0hVSWdEWFA4S3pxMWFpWHdGMERoZ245VzdwMFRyaWhLV0RiNExvNzE1czZSbE41ZjdEWUI4aDV4VTBMUEYzQ1FWUl9mbDgzUFQ4?oc=5","date":"2023-10-11","type":"deal","source":"Fierce Pharma","summary":"Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions - Fierce Pharma","headline":"Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNQUJPYXk0Y3dERjAxRVRmYVdvV1ZOSVRTYXI2eTgxOVVRWjdPUlNnZy1UanR3MldJN1d3TVEwOFR4SWkwaEJRZmpoOGtSN09iMmdvYjZkSk4zRVJBQXFNaFdOeG5QWm8yLVlhOEVpQmRiaHY5WkJ2akx6d0FFaVZKelZKT3ZIM2hibzNGWkNiQXcxWlAzci1nN2hOdnQ4dC1JNDNsRzktZEFQUW9PdmVBakM3SlA?oc=5","date":"2023-09-26","type":"pipeline","source":"Biogen","summary":"Biogen Completes Acquisition of Reata Pharmaceuticals - Biogen","headline":"Biogen Completes Acquisition of Reata Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPLVJDWnFuNGd0ZzFDREw3U1E5cnFidzh5TmdtY1NXSURzX1ExRlp1Q25rN2Z5ZmJWM21DOWQwMTFlaThwdkgwUUc0NjduMWFGdFdkSzh4QW9pVFdEMHR5WUhtYzRiblBRLVhUbDZ3bVNXNEluQ19GVjNFYnpyUWZqdkhaQTFYVnZPQ3VLcFFhd05tLXBKNlJwdW8zNG5SSG9kcXJyNFJYN3BkMVpkblJMVmhIQ3VKa0o4?oc=5","date":"2023-09-12","type":"deal","source":"TipRanks","summary":"Reata says waiting period related to merger under Hart-Scott-Rodino act expired - TipRanks","headline":"Reata says waiting period related to merger under Hart-Scott-Rodino act expired","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNZXlxZ2NGdUVoT3A0SlloQ1M5NkkzVWE1RU00dXd4N2p1V2pYTHhhcWJtZEdRTkthNURQaGpSLVdNbTd2eU9MQnBWT2RMMmtfSVpJY1l5QTZfU2dDX3l6bnlvb1FQUEFqWW5OMXNkeXliLXlZWXllc2thWllHN3VEM1hMcmphNnhEcWlBM05MaG1EeS1R?oc=5","date":"2023-08-15","type":"pipeline","source":"Fierce Pharma","summary":"How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B - Fierce Pharma","headline":"How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQcm5YeXpOeTFack9uNktBZWZKT1ZzTDNCaGk1aW96ZVNvcE1fdTMwdjZMT1dvM1hhOG9oMTdPUEdVX19WTTF1TGtBNjFDa3phMGYyTEdaOTFtaWg1R2o4WjlNUVU2YVF0S0gwMVMyVlA0UUlHWEVVNlFKU3FUQ1lSX3pvc09HWElQQWJVeA?oc=5","date":"2023-07-28","type":"pipeline","source":"MedCity News","summary":"Biogen Bulks Up in Rare Disease With $7.3B Reata Pharmaceuticals Acquisition - MedCity News","headline":"Biogen Bulks Up in Rare Disease With $7.3B Reata Pharmaceuticals Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVG9KUlloYmJrUUlXclJGcXdmc0JlV0RrSU1zMHhQNnNDcVRUdjUwSXBwLUdxa2Q1NmotQmgtdF9sMXR3YlFfN0RVbHRObmdqd1hjRHJ4enZlOTN6b1UtR3BPbjQtcGJ4ZC1mOXNJYi1rdXQ2WTRQNmE2SFhfdWdCTWw4QlVCN2x1ZWlmS3hLNXh1YXI4Mlg3U1NwSlJIc1RteHRkdE9UQjhoT1ZUZE5TRXAyVldhc2V4TXJj?oc=5","date":"2023-07-28","type":"pipeline","source":"Fierce Pharma","summary":"Biogen, amid layoffs, ponies up $7.3B for rare disease specialist Reata and potential blockbuster Skyclarys - Fierce Pharma","headline":"Biogen, amid layoffs, ponies up $7.3B for rare disease specialist Reata and potential blockbuster Skyclarys","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}